ENTITY
Brii Biosciences

Brii Biosciences (2137 HK)

35
Analysis
Health CareChina
Brii Biosciences operates as a biotechnology company. The Company discovers and develops therapeutics and medicines for the treatment of diseases. Brii Biosciences serves customers in the United States and China.
more
Refresh
15 Jul 2021 12:13

Kindstar (康圣环球) IPO Trading: Pattern of Demand Divergence

We look at the updates on Kindstar IPO since our last note. With its valuation higher than leading ICL peer, we do not expect a strong debut...

Logo
262 Views
Share
12 Jul 2021 12:52

Brii Biosciences (腾盛博药) IPO Trading: Note the Pre-IPO Investors Subscription

We look at the updates since our last note for Brii. We note that the allocation to institutional investors were heavily concentrated in the...

Logo
316 Views
Share
04 Jul 2021 10:21

ECM Weekly (4th July 2021) - Xpeng, Medbot, Medlive, Brii Bio, CTOS, LinkDoc, Devyani, Manycore

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
30 Jun 2021 12:48

Brii Biosciences (腾盛博药) IPO: Not a Demanding Valuation for Its Differentiation

We provide an update for the book building of Brii IPO. We think the valuation of the deal is not demanding with upside for investors.

Logo
461 Views
Share
28 Jun 2021 10:11

Brii Biosciences (腾盛博药) Pre-IPO: Thoughts on Valuation

We provide our thoughts on the pre-money valuation for Brii Biosciences. We valued the BRII-179/BRII-835 for HBV and BRII-778/BRII-732 for HIV...

Logo
323 Views
Share
x